Researchers have identified a blood biomarker that could help track the progression of multiple sclerosis (MS) and monitor how patients respond to treatment, according to a study published in 2026. The marker, known as serum neurofilament light chain (sNfL), reflects nerve cell damage and has been studied as a potential tool for managing MS.
The study, which involved [number] participants, found that higher levels of sNfL were associated with more severe disability and disease activity. The findings suggest that regular blood tests could complement MRI scans in evaluating disease progression and the effectiveness of therapies.
Experts caution that while sNfL is promising, it is not yet ready for routine clinical use. Further validation in larger, diverse populations is needed before it can be widely adopted. The research was presented at [conference] and published in [journal].
For people living with MS, a simple blood test could eventually provide a less invasive way to monitor their condition, potentially leading to more personalized treatment adjustments. However, patients should continue to follow their neurologist's advice and current monitoring protocols.
